Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agreement”), with Futura Surgicare Pvt Ltd (“Futura”), an India-based leading manufacturer of wound closure and surgical products that are marketed and distributed in over 70 countries worldwide under the trade name “Dolphin Sutures”. Futura’s comprehensive and innovative product offering includes surgical sutures, skin staplers, hernia meshes, surgical tapes, hemostats, and bone wax.

The Agreement provides for (i) CCI to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products, and (ii) CCI and Futura to enter into a strategic partnership to introduce high-quality Dolphin Sutures and mesh products to the North American healthcare market, potentially bringing substantial cost savings and improved care to American patients and healthcare providers.

Dr. Joseph M. Chalil, MD, MBA, FACHE, President of CCI, remarked, "We are proud to partner with Futura in bringing Dolphin Sutures and mesh products to the North American market. FDA approval of these high-quality products would symbolize a beacon of hope in addressing the high costs of the American healthcare market. We are confident this partnership will mark a significant milestone in offering affordable and superior surgical solutions."

About Futura Surgicare Pvt Ltd

Futura Surgicare Pvt Ltd, under the stewardship of second-generation leader Abhijith Sagar, is pioneering the future of healthcare with cutting-edge surgical sutures, including Polyglycolic Acid, Polyglactin 910, PTFE, and Barbed sutures. Leveraging 30 years of industry leadership from Bangalore, India, the company is recognized for its firsts in synthetic absorbable sutures and its globally sourced high-quality materials. Upholding the highest standards, Futura is accredited with ISO 9001:2008, ISO 13485, CE2460, WHO-GMP, and GLP certifications. Abhijith Sagar exemplifies the transformative power of education and dedication as he guides Futura toward new horizons in medical innovation.